Zepbound tops Wegovy for weight loss in Eli Lilly study
1 day ago · Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk. Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk…
1 day ago · Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in
1 day ago · Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new clinical study. Zepbound patients lost an average 20% of their body weight compared ...
What the results of Wegovy’s longest clinical trial yet show about ...
May 13, 2024 · More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a...
News Details - Novo Nordisk
Jul 25, 2024 · The SELECT trial demonstrated that Wegovy ® statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care.
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk.
Ozempic, Wegovy maker Novo Nordisk faces hearing over high …
Sep 24, 2024 · Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO testified on Capitol Hill Tuesday.
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti …
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along ...
News Details - Novo Nordisk
Nov 11, 2021 · “With the unprecedented and sustained weight loss for an anti-obesity medication, Wegovy™ has the potential to transform obesity management and help millions of people living with obesity,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk.